Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Teligent, Inc.(Nasdaq: TLGT), ("Teligent" or the "Company"), aNew Jersey based generics pharmaceutical company, today announced they will hold a conference call at8:30AM ETonTuesday, May 25th, 2021 to discuss the firstquarter ended March 31, 2021 financial results and business update.


GlobeNewswire Inc | May 21, 2021 04:30PM EDT

May 21, 2021

BUENA, N.J., May 21, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc.(Nasdaq: TLGT), ("Teligent" or the "Company"), aNew Jersey based generics pharmaceutical company, today announced they will hold a conference call at8:30AM ETonTuesday, May 25th, 2021 to discuss the firstquarter ended March 31, 2021 financial results and business update.

Conference Call InformationDate: Tuesday, May 25, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: (866) 393-8366 International: 409-350-3154Conference ID:4758457

This call is available via webcast and can be accessed under News & Events in the Investor Relations section ofTeligent, Inc.'swebsite atwww.teligent.com.

AboutTeligent, Inc.Teligentis a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our websitewww.teligent.com.

Forward-Looking StatementsThis press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as plan, believe, continue, should or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to successfully complete future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption Risk Factors inTeligent, Inc.s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with theSecurities and Exchange Commission.Teligent, Inc.does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

Investors:InvestorRelations@Teligent.com

and

Tim McCarthytim@lifesciadvisors.com

View original content: SOURCETeligent, Inc.







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC